What’s driving Hepion Pharmaceuticals, Inc.’s (NASDAQ:HEPA) share price on post-market sessions?

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA)stock surged 24.52% to $2.59 in the late hours last night after its Topline results have been announced from the Phase’s low dose cohort 2a ‘AMPITION’ clinical trial of CRV431, a novel cyclophilin inhibitor orally administered once daily.Phase 2a study of CRV431 is continuing at a higher dose of 225 mg, with CRV431 patient dosing expected in Q1-2021.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

A CRV431 study called the AMBITION trial will be conducted among patients with moderate-to-severe fibrosis and NASH evidence.Researchers at 10 U.S. sites are administering 75 mg of CRV431 once-daily for 28 days in this study. An ongoing second cohort of 225 mg CRV431 (high dose) is being administered. We expect to have final results from both dosing cohorts once the high dose group has completed active dosing, followed by a 14-day observation period.